IL-23 Plasma level measurement in relapsing remitting multiple sclerosis (RRMS) patients compared to healthy subjects

Mansour Shajarian, Fereshteh Alsahebfosoul, Masoud Etemadifar, Nahid Sedaghat, Mansoureh Shahbazi, Fatemeh Pourgadegan Firouzabadi, Hoda Mohammad Dezashibi

Immunological Investigations · 2014 · 34 citations · 29 references

Concepts

Abstract

BACKGROUND: Multiple sclerosis (MS) is a chronic neuroinflammatory disease with unknown etiology and variable clinical evolution. Interleukin-23 (IL-23), a member of the IL-12 cytokine family is a heterodimeric cytokine composed of the IL-12p40 subunit, and with a novel p19 subunit, its ability to enhance the expansion of T helper type 17 (Th17) cells indicates the responsibility for many of the inflammatory autoimmune responses. OBJECTIVE: The objective of the project is to measure IL-23 level in plasma of multiple sclerosis (MS) patients in comparison with healthy control subjects. METHODS: In a case-control study, plasma was collected from healthy subjects as control group (n = 40) and patients with relapsing remitting multiple sclerosis (RRMS) (n = 40). The plasma level of IL-23 was assessed by ELISA method. Statistical analysis was performed with SPSS (Ver. 16). RESULTS: Plasma level of IL-23 in MS patients was significantly increased compared to control subjects (p Value < 0.001). CONCLUSIONS: Our findings revealed the increased IL-23 level in patients' group. In conclusion, the inhibition of IL-23 might be a novel and promising therapeutic strategy, especially in the therapy of autoimmune inflammatory diseases. IL-23 plays a pivotal role in development of MS and might be a specific marker and therapeutic target for MS.

References

29